Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 7/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | TP53 | P04637 | 3/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1977719 | 0.85 | TSHR (0.46) | TSHRHPGDALDH1A1TP53HIF1A | |
| Acrylic Acid SCHEMBL7620757 | 0.83 | TSHR (0.33) | TSHRTHRB | |
| SCHEMBL162366 | 0.82 | TSHR (0.54) | TSHRALDH1A1MAPK1 | |
| SCHEMBL21829112 | 0.81 | TSHR (0.63) | TSHRHPGDALDH1A1TP53HIF1A | |
| SCHEMBL27967446 | 0.81 | TSHR (0.52) | TSHRALDH1A1MAPK1 | |
| Ammonia Solution, Strong SCHEMBL7618985 | 0.81 | TSHR (0.52) | TSHRALDH1A1MAPK1 | |
| SCHEMBL1775598 | 0.81 | TSHR (0.52) | TSHRALDH1A1MAPK1 | |
| Lithium SCHEMBL38660899 | 0.81 | TSHR (0.52) | TSHRALDH1A1MAPK1 | |
| Water SCHEMBL17782175 | 0.79 | TSHR (0.50) | TSHRALDH1A1MAPK1 | |
| Acrylic Acid SCHEMBL1696538 | 0.78 | TSHR (0.48) | TSHRALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100233196-A1 | METHOD FOR PREPARING A VACCINE COMPOSITION COMPRISING AT LEAST ONE ANTIGEN AND AT LEAST ONE ADJUVANT | SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC (FR) | 2010-09-16 | — | — | US | claimed |
| US-9795565-B2 | Method for preparing a vaccine composition comprising at least one antigen and at least one adjuvant | Société d'Exploitation de Produits pour les Industries Chimiques SEPPIC (FR) | 2017-10-24 | — | — | US | disclosed |
| US-20100233196-A1 | METHOD FOR PREPARING A VACCINE COMPOSITION COMPRISING AT LEAST ONE ANTIGEN AND AT LEAST ONE ADJUVANT | SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC (FR) | 2010-09-16 | — | — | US | disclosed |
| US-20060210521-A1 | Composition containing a urea compound and an alkyl glycol carboxylate compound | L'OREAL (FR) | 2006-09-21 | — | — | US | disclosed |
| US-20060210518-A1 | Composition containing a urea compound and an oxyalkylenated compound | L'OREAL (FR) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060210521-A1 | Composition containing a urea compound and an alkyl glycol carboxylate compound | UNG, PCNA, SMURF1 | TSHR 3744/4885HPGD 1566/4885ALDH1A1 348/4885 |
| US-20060210518-A1 | Composition containing a urea compound and an oxyalkylenated compound | CUTA, C9, C1S | TSHR 4418/4885HPGD 1155/4885ALDH1A1 1193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.